Petros Pharmaceuticals Inc. (PTPI): Price and Financial Metrics

Petros Pharmaceuticals Inc. (PTPI): $0.71

0.08 (-9.97%)

POWR Rating

Component Grades

Momentum

F

Stability

F

Sentiment

Quality

F

PTPI Price/Volume Stats

Current price $0.71 52-week high $9.54
Prev. close $0.78 52-week low $0.66
Day low $0.66 Volume 1,984,871
Day high $0.90 Avg. volume 1,014,338
50-day MA $1.36 Dividend yield N/A
200-day MA $1.81 Market Cap 4.85M

PTPI Stock Price Chart Interactive Chart >


Petros Pharmaceuticals Inc. (PTPI) Company Bio


Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.


PTPI Latest News Stream


Event/Time News Detail
Loading, please wait...

PTPI Latest Social Stream


Loading social stream, please wait...

View Full PTPI Social Stream

Latest PTPI News From Around the Web

Below are the latest news stories about PETROS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PTPI as an investment opportunity.

Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)

New AI/machine learning tool designed to help potential users more effectively self-select in the effort to make STENDRA the first erectile dysfunction (ED) medication available OTCPetros in discussions with third-party technology partnersNEW YORK, ...

Yahoo | October 30, 2023

Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA

Important step towards STENDRA potentially becoming the first erectile dysfunction medication to successfully achieve OTC StatusNEW YORK, NY / ACCESSWIRE / October 19, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding ...

Yahoo | October 19, 2023

Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA Label

Company well positioned to continue collaboration with FDA toward pursuit of OTC pathway for STENDRANEW YORK, NY / ACCESSWIRE / October 4, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication ...

Yahoo | October 4, 2023

Petros Pharmaceuticals to Present at the LD Micro Main Event XVI

NEW YORK, NY / ACCESSWIRE / September 28, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway, announces today that Fady Boctor, President and Chief ...

Yahoo | September 28, 2023

Petros Pharmaceuticals Provides Letter to Shareholders

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway provides the below Letter to Shareholders:

Yahoo | September 11, 2023

Read More 'PTPI' Stories Here

PTPI Price Returns

1-mo -53.29%
3-mo -40.34%
6-mo -54.20%
1-year -81.61%
3-year -97.75%
5-year N/A
YTD -49.65%
2023 -39.48%
2022 -93.00%
2021 -24.32%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!